NU Lin

This study analyzes genomic alterations in a large IBC cohort, finding high TP53 mutation frequency and NOTCH pathway enrichment, but no major genomic differences compared to non-IBC cases.

This study finds that 5% of breast cancers have high tumor mutation burden, more common in metastatic tumors, with APOBEC activity as the most common mutational process and potential benefit from PD-1 inhibitors.